These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15470277)

  • 1. HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure.
    Hurwitz BE; Klimas NG; Llabre MM; Maher KJ; Skyler JS; Bilsker MS; McPherson-Baker S; Lawrence PJ; Laperriere AR; Greeson JM; Klaus JR; Lawrence R; Schneiderman N
    Cardiovasc Toxicol; 2004; 4(3):303-16. PubMed ID: 15470277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ten-year predicted coronary heart disease risk in HIV-infected men and women.
    Kaplan RC; Kingsley LA; Sharrett AR; Li X; Lazar J; Tien PC; Mack WJ; Cohen MH; Jacobson L; Gange SJ
    Clin Infect Dis; 2007 Oct; 45(8):1074-81. PubMed ID: 17879928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular effects of antiretroviral drugs: clinical review.
    Filardi PP; Paolillo S; Marciano C; Iorio A; Losco T; Marsico F; Scala O; Ruggiero D; Ferraro S; Chiariello M
    Cardiovasc Hematol Disord Drug Targets; 2008 Dec; 8(4):238-44. PubMed ID: 19075633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.
    Rose H; Woolley I; Hoy J; Dart A; Bryant B; Mijch A; Sviridov D
    Metabolism; 2006 Jan; 55(1):90-5. PubMed ID: 16324925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir.
    Walli RK; Michl GM; Bogner JR; Goebel FD
    Eur J Med Res; 2001 Oct; 6(10):413-21. PubMed ID: 11698228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
    Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T
    Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome among HIV infected patients: A comparative cross sectional study in northwestern Nigeria.
    Muhammad FY; Gezawa ID; Uloko A; Yakasai AM; Habib AG; Iliyasu G
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S523-S529. PubMed ID: 28410829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients.
    Asztalos BF; Schaefer EJ; Horvath KV; Cox CE; Skinner S; Gerrior J; Gorbach SL; Wanke C
    Atherosclerosis; 2006 Jan; 184(1):72-7. PubMed ID: 15935358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
    Crane HM; Van Rompaey SE; Kitahata MM
    AIDS Patient Care STDS; 2007 Dec; 21(12):920-9. PubMed ID: 18154489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metabolic and cardiovascular effects of combined antiretroviral therapy in patients with HIV infection. Systematic review of literature].
    Casaretti L; Paolillo S; Formisano R; Bologna A; Mattiello G; Conte S; Petraglia L; Lo ludice F; Fabiani I; Cirillo AP; Vitagliano A; Gambardella F; della Ratta GL; Filardi PP
    Monaldi Arch Chest Dis; 2011 Dec; 76(4):175-82. PubMed ID: 22567733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment.
    Schrooten W; Colebunders R; Youle M; Molenberghs G; Dedes N; Koitz G; Finazzi R; de Mey I; Florence E; Dreezen C;
    AIDS; 2001 May; 15(8):1019-23. PubMed ID: 11399984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.
    Patroni A; Torti C; Tomasoni L; Quiros Roldan E; Bertelli D; Puoti M; Cadeo GP; Sleiman I; Tinelli C; Carosi G; Castelli F
    HIV Clin Trials; 2002; 3(6):451-61. PubMed ID: 12501128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nutritional assessment and lipid profile in HIV-infected children and adolescents treated with highly active antiretroviral therapy.
    Tremeschin MH; Sartorelli DS; Cervi MC; Negrini BV; Salomão RG; Monteiro JP
    Rev Soc Bras Med Trop; 2011; 44(3):274-81. PubMed ID: 21739071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy.
    Barbaro G; Di Lorenzo G; Cirelli A; Grisorio B; Lucchini A; Hazra C; Barbarini G
    Clin Ther; 2003 Sep; 25(9):2405-18. PubMed ID: 14604740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Thomas-Geevarghese A; Raghavan S; Minolfo R; Holleran S; Ramakrishnan R; Ormsby B; Karmally W; Ginsberg HN; El-Sadr WM; Albu J; Berglund L
    Am J Clin Nutr; 2005 Jul; 82(1):146-54. PubMed ID: 16002813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996-99.
    Thiébaut R; Dequae-Merchadou L; Ekouevi DK; Mercié P; Malvy D; Neau D; Dabis F;
    HIV Med; 2001 Apr; 2(2):84-8. PubMed ID: 11737383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.